Synapse - Monica Fornier

Results (158)

Adjuvant chemotherapy for primary breast cancer

Journal Article

Fornier, M.; Hudis, C.
Current Oncology Reports (2005)

A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors

Meeting Abstract

Rathkopf, D.; Fornier, M.; Shah, M.; Kortmansky, J.; O'reilly, E.; King, A.; Winkelmann, J.; Kelsen, D. P.; Olsen, S.; Schwartz, G. K.
Journal of Clinical Oncology (2004)

Fulltext@MSK | Save

Phase I dose-finding study of weekly (W) docetaxel (T) followed by flavopiridol (F) for patients with metastatic solid tumors

Meeting Abstract

Fornier, M. N.; Rathkopf, D.; Shah, M.; Hudis, C.; O'reilly, E.; Kortmansky, J.; Winkelmann, J.; Kelsen, D.; Norton, L.; Schwartz, G. K.
Annals of Oncology (2004)

Fulltext@MSK | Save

Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy

Meeting Abstract

Esteva, F. J.; Cheli, C.; Fritsche, H. A.; Fornier, M.; Slamon, D. J.; Thiel, R. P.; Luftner, D.; Ghani, F.
Breast Cancer Research and Treatment (2004)

Fulltext@MSK | Save

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer

Journal Article

Dang, C. T.; D'Andrea, G. M.; Moynahan, M. E.; Dickler, M. N.; Seidman, A. D.; Fornier, M.; Robson, M. E.; Theodoulou, M.; Lake, D.; Currie, V. E.; more...
Clinical Cancer Research (2004)

Fulltext@MSK | Save

Risk models for neutropenia in patients with breast cancer

Journal Article

Dang, C. T.; Fornier, M. N.; Hudis, C. A.
Oncology (Norwalk) (2003)

Fulltext@MSK | Save

Incidence of amenorrhea (A) in breast cancer (BC) patients (pts) <= 40 years of age after paclitaxel (T)-based adjuvant chemotherapy (CT)

Meeting Abstract

Fornier, M. N.; Modi, S.; Hudis, C. A.
Breast Cancer Research and Treatment (2002)

Fulltext@MSK | Save

Serum HER2 extracellular domain (ECD) correlates with HER2 status by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) in metastatic breast cancer (MBC) patients (pts) treated with weekly (W) trastuzumab (H) and paclitaxel (T)